Qin Zhang
14
5
5
9
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 14 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 9 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (14)
The Kallikrein-Kinin System in Cardiac Surgery
Role: lead
Role of the Kallikrein-kinin System in Septic Cardiomyopathy
Role: lead
Opioid-Free Pain Management After NUSS Surgery in Adolescents
Role: lead
Ulinastatin Reduces Postoperative Pulmonary Complications in Cardiac Surgery
Role: lead
The Association Between Obesity-Related Indicators and Adverse Outcomes in Ischemic Stroke Patients
Role: lead
Ulinastatin Improves and Prevents Cardiac Dysfunction Induced by Cardiopulmonary Bypass
Role: lead
Ulinastatin Improves Post-Cardiac Surgery Cognitive Dysfunction
Role: lead
Risk Factors for Adverse Outcomes in Sepsis
Role: lead
Tissue Kallikrein Protect Against Ischemic Stroke
Role: lead
Effect of Percutaneous Acupoint Electrical Stimulation on Delirium
Role: lead
Bedside Renal Ultrasound Assessment in Patients With Acute Kidney Injury
Role: lead
Liver Ischemia-reperfusion Injury and Clinical Data Analysis
Role: lead
Transcutaneous Acupoint Electrical Stimulation and Postoperative Delirium Delirium
Role: lead
Postoperative Delirium in the Post-anesthesia Care Unit
Role: lead
All 14 trials loaded